Identification of High-Performing Safety Net Hospitals for Radical Cystectomy: Implications for National Cancer Institute Cancer Center Partnership Familial adenomatous polyposis (FAP) is an autosomal ...

ST316 interfered with β-catenin immune-exclusion allowing for stronger cytotoxic T-cell activity. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ST316 for the treatment ...

Familial adenomatous polyposis is an inherited condition that significantly increases the risk for colon cancer. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TPST-1495 ...

Please provide your email address to receive an email when new articles are posted on . For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower ...

Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), ...

In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC gene induce the formation of intestinal polyps, but also reduce immune system ...

Biodexa Pharmaceuticals PLC announced that the European Commission has granted Orphan Drug Designation for its drug eRapa, aimed at treating familial adenomatous polyposis (FAP), a hereditary ...

March is Colorectal Cancer Awareness Month — a timely opportunity to learn about colorectal cancer, understand your risk.